Home・Список акций・AbCellera Biologics Inc

AbCellera Biologics Inc

Закрыт

СекторЗдравоохранение

6.44 4.04

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

5.71

Макс.

6.55

Ключевые показатели
By Trading Economics
Доход	-34M -43M
Продажи	-37M 8.3M
Прибыль на акцию	-0.14
Рентабельность продаж	-519.122
Сотрудники	562
EBITDA	-23M -41M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+82.94% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	178M 1.8B
Предыдущая цена открытия	2.4
Предыдущая цена закрытия	6.44

Новостные настроения

By Acuity

47%

53%

159 / 340 Рейтинг в Healthcare

AbCellera Biologics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 авг. 2026 г., 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 авг. 2026 г., 23:02 UTC

Social Media

News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 авг. 2026 г., 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 июл. 2026 г., 19:33 UTC

Correlated Moves

Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 июл. 2026 г., 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 июл. 2026 г., 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28 июл. 2026 г., 19:41 UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27 июл. 2026 г., 19:46 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24 июл. 2026 г., 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22 июл. 2026 г., 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21 июл. 2026 г., 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 июл. 2026 г., 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Сравнение c конкурентами

Изменение цены

AbCellera Biologics Inc Прогноз

Целевая цена

By TipRanks

82.94% рост

Прогноз на 12 месяцев

Средняя 10.83 USD 82.94%

Максимум 13 USD

Минимум 7 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для AbCellera Biologics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

Покупка

Удержание

Продажа

Основано на мнении 7 аналитиков, присваивавших рейтинги акциям AbCellera Biologics Inc – Данные за последние 3 месяца.

Настроения

By Acuity

159 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.